WO2005035505A3 - Compounds with phosphodiesterase inhibiting and calcium channel blocking activities - Google Patents

Compounds with phosphodiesterase inhibiting and calcium channel blocking activities Download PDF

Info

Publication number
WO2005035505A3
WO2005035505A3 PCT/US2004/026810 US2004026810W WO2005035505A3 WO 2005035505 A3 WO2005035505 A3 WO 2005035505A3 US 2004026810 W US2004026810 W US 2004026810W WO 2005035505 A3 WO2005035505 A3 WO 2005035505A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
calcium channel
channel blocking
blocking activities
phosphodiesterase inhibiting
Prior art date
Application number
PCT/US2004/026810
Other languages
French (fr)
Other versions
WO2005035505A2 (en
Inventor
Gregory S Hamilton
Original Assignee
Artesian Therapeutics Inc
Gregory S Hamilton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Artesian Therapeutics Inc, Gregory S Hamilton filed Critical Artesian Therapeutics Inc
Publication of WO2005035505A2 publication Critical patent/WO2005035505A2/en
Publication of WO2005035505A3 publication Critical patent/WO2005035505A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

The present invention provides compounds that possess inhibitory activity against PDE-3 and L-type calcium channels. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating cardiovascular disease, stroke, epilepsy, ophthalmic disorder or migraine.
PCT/US2004/026810 2003-09-30 2004-08-18 Compounds with phosphodiesterase inhibiting and calcium channel blocking activities WO2005035505A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50672003P 2003-09-30 2003-09-30
US60/506,720 2003-09-30

Publications (2)

Publication Number Publication Date
WO2005035505A2 WO2005035505A2 (en) 2005-04-21
WO2005035505A3 true WO2005035505A3 (en) 2006-01-05

Family

ID=34434884

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/026810 WO2005035505A2 (en) 2003-09-30 2004-08-18 Compounds with phosphodiesterase inhibiting and calcium channel blocking activities

Country Status (1)

Country Link
WO (1) WO2005035505A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004011512B4 (en) 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical preparation containing pimobendan
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
CN102223882B (en) * 2008-11-25 2016-02-03 贝林格尔.英格海姆维特梅迪卡有限公司 Be used for the treatment of III type phosphodiesterase (PPE III) inhibitor or the Ca of hypertrophic cardiomyopathy 2+sensitizer
US20120039973A1 (en) * 2010-08-11 2012-02-16 Paul Grlica Composition and method of time releasing essential oils for animal repellency and pesticide use
US10398705B2 (en) 2012-03-15 2019-09-03 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
JP6272475B2 (en) 2013-07-19 2018-01-31 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハーＢｏｅｈｒｉｎｇｅｒ Ｉｎｇｅｌｈｅｉｍ Ｖｅｔｍｅｄｉｃａ ＧｍｂＨ Liquid aqueous pharmaceutical composition containing antiseptic etherified cyclodextrin derivative
DK3106150T3 (en) 2013-12-04 2021-11-01 Boehringer Ingelheim Vetmedica Gmbh IMPROVED PHARMACEUTICAL COMPOSITIONS OF PIMOBENDAN
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
CN111447930A (en) 2017-11-23 2020-07-24 奥斯陆大学医院公司 Treatment of tachycardia

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0256888A1 (en) * 1986-08-20 1988-02-24 McNeilab, Inc. Benzothiazepine vasodilators having aralkyl substitution
EP0391414A2 (en) * 1989-04-06 1990-10-10 E.R. SQUIBB & SONS, INC. Benzazepine and benzothiazepine derivatives
EP0391107A1 (en) * 1989-04-04 1990-10-10 E.R. SQUIBB & SONS, INC. Benzazepine derivatives
EP0424214A1 (en) * 1989-10-17 1991-04-24 Synthelabo 5-[2-[[2-Amino-2-oxoethyl]methylamino]ethyl]-2,3-dihydro-3-hydroxy-2-(4-methoxyphenyl)-1,5(5H)-benzothiazepine-4-one derivatives, their preparation and their use in therapy
WO2004033444A1 (en) * 2002-10-07 2004-04-22 Artesian Therapeutics, Inc. Dihydropyridine compounds having simultaneous ability to block l-type calcium channels and to inhibit phosphodiesterase type 3 activity

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0256888A1 (en) * 1986-08-20 1988-02-24 McNeilab, Inc. Benzothiazepine vasodilators having aralkyl substitution
EP0391107A1 (en) * 1989-04-04 1990-10-10 E.R. SQUIBB & SONS, INC. Benzazepine derivatives
EP0391414A2 (en) * 1989-04-06 1990-10-10 E.R. SQUIBB & SONS, INC. Benzazepine and benzothiazepine derivatives
EP0424214A1 (en) * 1989-10-17 1991-04-24 Synthelabo 5-[2-[[2-Amino-2-oxoethyl]methylamino]ethyl]-2,3-dihydro-3-hydroxy-2-(4-methoxyphenyl)-1,5(5H)-benzothiazepine-4-one derivatives, their preparation and their use in therapy
WO2004033444A1 (en) * 2002-10-07 2004-04-22 Artesian Therapeutics, Inc. Dihydropyridine compounds having simultaneous ability to block l-type calcium channels and to inhibit phosphodiesterase type 3 activity

Also Published As

Publication number Publication date
WO2005035505A2 (en) 2005-04-21

Similar Documents

Publication Publication Date Title
MXPA05003640A (en) Dihydropyridine compounds having simultaneous ability to block l-type calcium channels and to inhibit phosphodiesterase type 3 activity.
WO2007021941A3 (en) Inhibitors of voltage-gated sodium channels
WO2003037900A3 (en) Pyrazolopyrimidines
WO2003037274A3 (en) Pyrazole-amides and-sulfonamides
WO2007002884A3 (en) 4-fluoro-piperidine t-type calcium channel antagonists
HK1092467A1 (en) N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses n-
WO2006091395A3 (en) Inhibitors of akt activity
WO2003037890A3 (en) Piperidines
WO2003039460A3 (en) Mitotic kinesin inhibitors
WO2004028454A3 (en) 1, 3, 5-triazines for treatment of viral diseases
WO2003049678A3 (en) Mitotic kinesin inhibitors
WO2003050064A3 (en) Mitotic kinesin inhibitors
WO2003049527A3 (en) Mitotic kinesin inhibitors
WO2003049679A3 (en) Mitotic kinesin inhibitors
WO2003050122A3 (en) Mitotic kinesin inhibitors
WO2007002361A3 (en) 3-fluoro-piperidine t-type calcium channel antagonists
WO2004105700A3 (en) Compounds, methods and pharmaceutical compositions for inhibiting parp
WO2006135627A3 (en) Inhibitors of akt activity
WO2006110638A3 (en) Inhibitors of akt activity
WO2003099211A3 (en) Mitotic kinesin inhibitors
WO2006060127A3 (en) COMPOUNDS WITH MIXED PDE-INHIBITORY AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE
WO2004009559A3 (en) Dihydrouracil compounds as anti-ictogenic or anti-epileptogenic agents
WO2003105840A3 (en) Sphingosine kinase inhibitors
WO2005007141A3 (en) Ubiquitin ligase inhibitors and methods related thereto
WO2006098969A3 (en) Quinazolinone t-type calcium channel antagonists

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 69(1) EPC (EPO FORM 1205A DATED 13.06.2006)

122 Ep: pct application non-entry in european phase